KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Retained Earnings (2016 - 2025)

NovoCure (NVCR) has disclosed Retained Earnings for 12 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 99.7% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.4 million through Dec 2025, up 99.7% year-over-year, with the annual reading at -$3.4 million for FY2025, 99.7% up from the prior year.
  • Retained Earnings hit -$3.4 million in Q4 2025 for NovoCure, up from -$5.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$1.3 million in Q1 2022 to a low of -$1.2 billion in Q2 2025.
  • Historically, Retained Earnings has averaged -$497.9 million across 5 years, with a median of -$639.0 million in 2021.
  • Biggest five-year swings in Retained Earnings: soared 99.79% in 2022 and later crashed 62514.53% in 2023.
  • Year by year, Retained Earnings stood at -$3.2 million in 2021, then grew by 23.22% to -$2.4 million in 2022, then tumbled by 40405.67% to -$985.5 million in 2023, then decreased by 17.11% to -$1.2 billion in 2024, then skyrocketed by 99.7% to -$3.4 million in 2025.
  • Business Quant data shows Retained Earnings for NVCR at -$3.4 million in Q4 2025, -$5.8 million in Q3 2025, and -$1.2 billion in Q2 2025.